For instance, IDH-mutated gliomas exhibit selective responses to the IDH1/2 dual-target inhibitor Vorasidenib, while leukemia patients carrying KMT2A rearrangements or NPM1 mutations. The gene discussed is IDH2; the disease is central nervous system cancer.